Belvedere Trading’s Roivant Sciences ROIV Stock Holding History

Belvedere Trading’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-5,472	Closed	-$63.9K	–	965
2023 Q3	$63.9K	Buy	+5,472	New	+$61.9K	﹤0.01%	395
2023 Q2	–	Sell	-5,054	Closed	-$37.3K	–	1080
2023 Q1	$37.3K	Buy	+5,054	New	+$41.6K	﹤0.01%	633

Other funds holding ROIV

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PSC

Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

Belvedere Trading's ROIV Position: Q4 2023 in Review

Belvedere Trading sold out of Roivant Sciences (ROIV) in Q4 2023, closing a stake of 5,472 shares — an estimated $63.9K sold.

Belvedere Trading first reported a position in ROIV in Q1 2023 and held it in 2 quarters. The position peaked at $63.9K in Q3 2023. 224 funds tracked by Wall St. Rank hold ROIV as of Q4 2023.

Belvedere Trading reported no remaining Roivant Sciences position as of Q4 2023 after selling out during the quarter.
Belvedere Trading sold 5,472 Roivant Sciences shares in Q4 2023, an estimated $63.9K.
Belvedere Trading first reported a position in Roivant Sciences in Q1 2023 and held it in 2 quarters.
Belvedere Trading's Roivant Sciences position peaked at $63.9K in Q3 2023.
224 funds tracked by Wall St. Rank held Roivant Sciences as of Q4 2023.

Based on Belvedere Trading's 13F filing for Q4 2023, filed 13 Feb 2024.